Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D9421-C vs Mesalazine in Active Crohn's Disease
NCT01514240Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2012
- Primary completion
- Sep 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of EPI-EE in Crohn's disease, sponsored by AstraZeneca. Started Feb 2012; status: completed.
02
Drugs
EPI-EE
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01514240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01514240.